Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentostatin and Rituximab With or Without Cyclophosphamide in Previously Untreated B-CLL
NCT00201721Phase 2Completed
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jul 2002
- Primary completion
- Jul 2006
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised trial in chronic lymphocytic leukemia (CLL) comparing Pentostatin + Rituximab with Pentostatin + Rituximab + Cyclophosphamide (2 arms). Primary endpoint: Complete and Overall Response Rate up to 5 years. Started Jul 2002; status: completed.
02
Drugs
pentostatinrituximabcyclophosphamide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00201721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00201721.